The revision to USP General Chapter ‹1› would force pharmaceutical manufacturers to abandon certain technologies that have been used to improve patient safety and to help combat the growing threat of drug counterfeiting. As a result, patient safety and supply-chain security may suffer.
In the world of healthcare administration and pharmaceutical product development, nothing is more important than patient safety. Pharmaceutical companies go to extraordinary lengths to help ensure that the products they market are not only efficacious, but also are safe for patients and healthcare providers.Packaging benefits and limits
Drug packaging is designed with this safety in mind. Elastomeric stoppers used for drug vials are manufactured from clean formulations and incorporate films and coatings to protect the packaged drug against leachables. The vials themselves are manufactured from inert materials that help protect drug purity against similar effects as well as particles. The stopper and vial are secured by a secondary seal that consists of an aluminum shell (ferrule) and plastic button (cap). Crimping the seal to the vial keeps contaminants from entering the vial.
The seal plays another vital role in patient safety. Instructions printed on the plastic buttons and aluminum shells provide those who administer the injectable drug with valuable information at the point of administration. This information often serves as a final check for healthcare providers to help ensure that the correct drug in the correct strength is being given to the patient. In addition, it is common industry practice to print or emboss unique product identifiers on caps and shells that help to identify products as genuine at the point of use. These measures are increasingly important as more and more counterfeit drugs make their way into the supply chain. The technologically sophisticated markings can be torturous for counterfeiters to copy.
Despite efforts to prevent medication errors, they do occur. In 2007, six infants were mistakenly given adult doses of the drug heparin in an Indianapolis hospital. Three of the babies died.
Heparin is commonly used in hospitals and there is little difference between the packaging used for the 10-unit pediatric dose and the 10,000-unit adult dose. The vials are identical in size and shape. The only difference is the shade of the blue plastic button, which may not be sufficient to differentiate the two if they are not seen together. One safety solution for heparin could encompass printing dosage strength on the plastic button and aluminum shell, a solution that would be proscribed by the revised USP ‹1›.
Pharmaceutical companies print and emboss a variety of messages on plastic buttons and seals that would be prohibited by the revised USP ‹1›. Examples include:
The aluminum shell provides a platform for important messages as well.
Printing on the shell can be concealed until the plastic button is removed, providing covert protection against counterfeiting. Some pharmaceutical companies use a clear plastic button so the message printed on the seal is visible before the button is removed. Such applications provide valuable point-of-administration information and can be an effective anticounterfeiting measure because the plastic button cannot be reattached after it is removed.
The revised USP ‹1› would allow cautionary statements to be printed on the plastic cap and seal. A cautionary statement may include: "Warning: Paralyzing Agent" and "Must Be Diluted." Such warnings are currently printed on plastic buttons and seals for several drugs.